GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Burzynski Research Institute BZYR · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$1.4m

FY2016FY2025

Free cash flow

−$388,531

FY2016FY2025

Shareholders' equity

−$41,637

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit————————−$684−$684
Research and development$1.0m$865,000$718,505$759,510$1.0m$1.2m$1.1m$1.3m$1.3m$1.8m
Operating income−$1.4m−$1.3m−$916,292−$976,656−$1.3m−$1.6m−$1.6m−$1.6m−$1.5m−$2.0m
Net income−$1.4m−$1.3m−$916,292−$976,656−$1.2m−$1.6m−$1.6m−$1.6m−$1.5m−$2.0m
Diluted earnings per share-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.02

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$847$2,310$1,934$4,661$956$19,853$22,172$28,929$10,731$3,987
Cash and short-term investments$847$1,310$934$3,382$62$163$708$506$731$3,303
Total liabilities$42,484$27,433$15,661$3,455$46,799$172,440$208,820$136,629$43,732$105,005
Shareholders' equity−$41,637−$25,123−$13,727$1,206−$45,843−$152,587−$186,648−$107,700−$33,001−$101,018
Shares outstanding131m131m131m131m131m131m131m131m131m131m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$388,531−$523,780−$249,516−$325,098−$394,369−$530,113−$477,516−$319,493−$314,515−$251,016
Free cash flow−$388,531−$523,780−$249,516−$325,098−$394,369−$530,113−$477,516−$319,493−$314,515−$251,016

Latest quarters

By quarter end

Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024
Operating income−$328,862−$333,867−$331,451−$292,798−$352,239−$369,838−$371,330−$362,907
Net income−$328,862−$333,867−$331,451−$292,798−$352,239−$369,838−$371,332−$362,907
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$2,265$1,331$1,521$847$713$1,616$997$2,310
Cash and short-term investments$2,165$931$821$847$613$1,216$297$1,310
Shareholders' equity−$67,343−$69,571−$69,716−$41,637−$21,326−$87,634−$127,868−$25,123

Growth per year

Compound annual rate

3 years5 years10 years
Operating income12.4%-3.2%-7.1%
Net income12.4%-3.2%-7.1%

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-0.1-0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return360%1001%461%169%4109%14333%13711%259%223%9355%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.